{"denoms":[{"counts":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"80"}],"units":"Participants"}],"groups":[{"description":"Patients undergoing ASCT for MM who were ≥60 years old or had AL amyloidosis were randomized to receive either a standard (4-6×106 cells/kg) of CD34+ cells after melphalan 200 mg/m2.","id":"BG000","title":"Standard Dose Stem Cell Group"},{"description":"Patients undergoing ASCT for MM who were ≥60 years old or had AL amyloidosis were randomized to receive high dose (10-15×106 cells/kg) of CD34+ cells after melphalan 200 mg/m2.","id":"BG001","title":"High Dose Stem Cell Group"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"42","upperLimit":"79","value":"64"},{"groupId":"BG001","lowerLimit":"37","upperLimit":"75","value":"65"},{"groupId":"BG002","lowerLimit":"37","upperLimit":"79","value":"65"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"25"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"55"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"80"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}